101 related articles for article (PubMed ID: 2093210)
21. Biotransformation of muroctasin in mice.
Matsubayashi K; Takegoshi T
Arzneimittelforschung; 1988 Jul; 38(7A):1015-8. PubMed ID: 3190793
[TBL] [Abstract][Full Text] [Related]
22. [Muroctasin, a muramyl dipeptide derivative].
Sosnowska D; Dzierzbicka K; Myśliwski A; Kołodziejczyk AM
Postepy Hig Med Dosw; 1992; 46(5):521-30. PubMed ID: 1298958
[TBL] [Abstract][Full Text] [Related]
23. Muramyl dipeptide and mononuclear cell supernatant induce Langhans-type cells from human monocytes.
Mizuno K; Okamoto H; Horio T
J Leukoc Biol; 2001 Sep; 70(3):386-94. PubMed ID: 11527988
[TBL] [Abstract][Full Text] [Related]
24. Subacute toxicity of muroctasin in mice and dogs.
Ono Y; Iwasaki T; Sekiguchi M; Onodera T
Arzneimittelforschung; 1988 Jul; 38(7A):1024-7. PubMed ID: 3190795
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
[TBL] [Abstract][Full Text] [Related]
26. Effects of muroctasin on the activities of drug metabolizing enzymes in liver microsomes of rats.
Kamataki T; Komori M; Iwasaki M; Ohi H; Kitada M; Miura T; Ono K
Arzneimittelforschung; 1988 Jul; 38(7A):1019-22. PubMed ID: 3263867
[TBL] [Abstract][Full Text] [Related]
27. Local tolerance of muroctasin injection in rabbits.
Nakashima K; Jindo T; Nomura M
Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
[TBL] [Abstract][Full Text] [Related]
28. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
[TBL] [Abstract][Full Text] [Related]
30. Antigenicity study of muroctasin.
Yamaguchi F; Hattori H; Wagai N; Tsukada W
Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
[TBL] [Abstract][Full Text] [Related]
31. Chronic toxicity of muroctasin in mice.
Ono Y; Sekiguchi M; Aihara K; Onodera T
Arzneimittelforschung; 1988 Jul; 38(7A):1028-30. PubMed ID: 3190796
[TBL] [Abstract][Full Text] [Related]
32. Phase I study and clinical pharmacological study of muroctasin.
Ichihara N; Kanazawa R; Sasaki S; Ono K; Otani T; Yamaguchi F; Une T
Arzneimittelforschung; 1988 Jul; 38(7A):1043-69. PubMed ID: 3263868
[TBL] [Abstract][Full Text] [Related]
33. General pharmacological properties of muroctasin.
Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
[TBL] [Abstract][Full Text] [Related]
34. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer.
Yanagawa H; Haku T; Takeuchi E; Suzuki Y; Nokihara H; Sone S
Lung Cancer; 2000 Feb; 27(2):67-73. PubMed ID: 10688489
[TBL] [Abstract][Full Text] [Related]
35. [Augmentation of immune defense mechanisms of the lung by romurtide].
Hasegawa J; Satoh A; Yagi K; Chida K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jun; 33(6):605-11. PubMed ID: 7666614
[TBL] [Abstract][Full Text] [Related]
36. Studies on the stability of muroctasin and degradation products built under extreme conditions.
Moroi R; Yamazaki K; Hirota T; Watanabe S; Oki M; Toriyama M; Ichinohe A; Kataoka K
Arzneimittelforschung; 1988 Jul; 38(7A):959-68. PubMed ID: 3190803
[TBL] [Abstract][Full Text] [Related]
37. Metabolic disposition of 14C-muroctasin in laboratory animals.
Ono K; Masayasu H; Hashimoto F; Yamada M; Takegoshi T
Arzneimittelforschung; 1988 Jul; 38(7A):1009-14. PubMed ID: 3190792
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.
Nakajima R; Ishida Y; Yamaguchi F; Otani T; Ono Y; Nomura M; Une T; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):986-92. PubMed ID: 3263871
[TBL] [Abstract][Full Text] [Related]
39. Suppression of Sendai virus growth by treatment with N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice.
Ishihara C; Mizukoshi N; Iida J; Kato K; Yamamoto K; Azuma I
Vaccine; 1987 Dec; 5(4):295-301. PubMed ID: 2448969
[TBL] [Abstract][Full Text] [Related]
40. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
